<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069001</url>
  </required_header>
  <id_info>
    <org_study_id>958</org_study_id>
    <nct_id>NCT03069001</nct_id>
  </id_info>
  <brief_title>Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV</brief_title>
  <official_title>Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Egyptian Patients With HCV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study was conducted at Ain Shams University Hospital, Internal Medicine,&#xD;
      Hepatology and Gastroenterology Department, and Tropical Medicine Department.&#xD;
&#xD;
      To compare the efficacy of the combination of sofosbuvir and simeprevir for 12 weeks with the&#xD;
      combination of sofosbuvir and ribavirin for 24 weeks in Egyptian patients with HCV-related&#xD;
      Child A cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation at end-of-treatment response</measure>
    <time_frame>12 weeks</time_frame>
    <description>undetectable HCV-RNA 12 weeks after the completion of therapy by a sensitive HCV-RNA assay</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir-Simeprevir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir 400 mg orally once-daily.&#xD;
Simeprevir 150 mg orally once-daily.&#xD;
Group A included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir-Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir 400 mg orally once-daily.&#xD;
Ribavirin orally twice-daily (according to body weight: 1000 mg daily in patients with a body weight of &lt;75 kg and 1200 mg daily in patients with a body weight of â‰¥75 kg).&#xD;
Group B included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir-Simeprevir</intervention_name>
    <description>-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.</description>
    <arm_group_label>Sofosbuvir-Simeprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir-Ribavirin</intervention_name>
    <description>-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.</description>
    <arm_group_label>Sofosbuvir-Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic HCV infection with a positive HCV RNA level by PCR.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Total bilirubin &gt; 2 mg/dl.&#xD;
&#xD;
          -  serum albumin &lt; 2.8 g/dl.&#xD;
&#xD;
          -  INR &gt; 1.7.&#xD;
&#xD;
          -  platelet count &lt; 50000/mm3.&#xD;
&#xD;
          -  serum creatinine &gt; 2.5 mg/dl.&#xD;
&#xD;
          -  patients presented by ascites or hepatic encephalopathy.&#xD;
&#xD;
          -  patients with evidence of other causes of liver diseases, including hepatitis A,&#xD;
             hepatitis B, autoimmune hepatitis, alcoholic liver disease, drug-induced hepatitis,&#xD;
             haemochromatosis, Wilson disease or alpha-1 antitrypsin deficiency.&#xD;
&#xD;
          -  patients with any advanced systemic disease.&#xD;
&#xD;
          -  pregnancy or inability to use effective contraception in females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Sara Abdelhakam</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HCV treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

